Recent Events & Catalysts
Travere Therapeutics, Inc. (TVTX) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78
Benzinga · 1d ago
Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha · 5d ago
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Benzinga · 5d ago
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75
Benzinga · 5d ago
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)
SeekingAlpha · 5d ago
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75
Benzinga · 6d ago
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85
Benzinga · 6d ago
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68
Benzinga · 6d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-04 · 7d ago · Material
Departure/appointment of directors or officers
Filed 2026-07-09 · 33d ago
Departure/appointment of directors or officers
Filed 2026-06-16 · 56d ago
Entry into a material agreement, Financial statements and exhibits
Filed 2026-06-02 · 70d ago
Departure/appointment of directors or officers, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-05-21 · 82d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.